Investigation of potential drug-drug interactions between faldaprevir and immunosuppressants (Cyclosporine and Tacrolimus) in healthy male and female subjects (Open-label, Fixed-sequence Trial)

Trial Profile

Investigation of potential drug-drug interactions between faldaprevir and immunosuppressants (Cyclosporine and Tacrolimus) in healthy male and female subjects (Open-label, Fixed-sequence Trial)

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Faldaprevir (Primary) ; Ciclosporin; Tacrolimus
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 30 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Feb 2014 According to the ClinicalTrials.gov record, Faldaprevir Alone and Faldaprevir in Combination With Deleobuvir arm groups were removed; number of patient changed from 64 to 32; and the primary end point C12ss was replaced with AUCt,ss.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top